Key result
The NOS3-4 polymorphism allele a was not associated with overall ESRD development but was associated with faster progression to ESRD in patients with autosomal dominant polycystic kidney disease (p=0.048).
Why the study?
Does the NOS3-4 gene polymorphism increase the risk of development or faster progression of end-stage renal disease in a Hellenic population?
Population
656 individuals from Greece and Cyprus, comprising 361 patients with end-stage renal disease and 295 healthy…
Comparison
NOS3-4 gene polymorphism (presence of allele a) vs Healthy controls or absence of allele a
Design
Case-control
Authors
Loading...
Does not support NOS3-4 testing for ESRD risk; leaves open possible faster ADPKD progression.
Case-Control (n=656)
Yes
Does the NOS3-4 gene polymorphism increase the risk of development or faster progression of end-stage renal disease in a Hellenic population?
The NOS3-4 gene polymorphism is not associated with overall ESRD development in a Hellenic population, but may be linked to faster progression in patients with ADPKD.
Lamnissou et al. (2004) conducted a case-control in End-stage renal disease (ESRD) (n=656). NOS3-4 polymorphism (allele a) vs. Healthy controls / allele b was evaluated on Development of ESRD. The NOS3-4 polymorphism allele a was not associated with overall ESRD development but was associated with faster progression to ESRD in patients with autosomal dominant polycystic kidney disease (p=0.048).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: